SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $1.48 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2026-03-31
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2025-09-30 was $1.48K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2023-03-31 was $90.82K, a 71.59% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2022-09-30 was $92.60K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2022-03-31 was $319.64K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2025 was $1.48K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2023 was $90.82K, a 519.40% increase from fiscal 2022.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2022 was $14.66K, a 96.40% decline from fiscal 2021.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2021 was $407.29K.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month as first filed | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month as first filed |
|---|---|---|---|---|
| 2025-12-31 | $1.48K 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $1.48K 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $90.82K 10-K · filed 2025-02-26 | |||
| 2023-03-31 | $90.82K 10-Q · filed 2024-11-13 | $99.54K 10-Q · filed 2023-05-25 | ||
| 2022-12-31 | $14.66K 10-K/A · filed 2024-09-04 | $412.24K 10-K · filed 2023-03-15 | ||
| 2022-09-30 | $92.60K 10-Q · filed 2023-11-13 | |||
| 2022-03-31 | $319.64K 10-Q · filed 2023-11-13 | |||
| 2021-12-31 | $407.29K 10-K · filed 2023-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |